生命科学资讯
生物技术与制药领域的最新动态
患者流失危机在招生开始前就已显现
The patient retention crisis is happening before enrollment even begins
当每一天都至关重要:在信任、关怀与精准基础上构建CRO合作关系
When every day counts: Building CRO partnerships on a foundation of trust, care and precision
Wegovy减肥药片市场反响热烈;前Emergent首席执行官因内幕交易被起诉
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
在生物科技的最大舞台上,重燃的兴奋面临压力测试。
On biotech’s biggest stage, renewed excitement gets a stress test
特朗普公布医疗可负担性计划
Trump unveils healthcare affordability plan
强生称Tecvayli在早期多发性骨髓瘤治疗中优于标准药物。
Tecvayli tops standard drugs in early multiple myeloma, J&J says
牛津生物医药确认与生物科技投资机构EQT进行收购谈判
Oxford Biomedica confirms takeover talks with biotech investor EQT
波士顿科学将以145亿美元收购Penumbra。
Boston Scientific to acquire Penumbra for $14.5B
摩根大通医疗年会:现金支付减肥药费用、IPO市场重燃乐观情绪及药企细胞疗法展望
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
礼来紧追诺和诺德,预计第二季度将获FDA对其减肥药的审批决定。
Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill
卡尔德拉公司以1.125亿美元启动,携中国双靶点免疫药物登场。
Caldera starts up with $112.5M and a dual-targeting immune drug from China
摩根大通26日:生物科技并购热潮,Biogen的“新生”与默克700亿美元目标
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target
报告显示:人工智能推动2025年数字健康领域融资增长
Digital health funding increases in 2025, spurred by AI: report
赛诺菲多发性硬化症困境对行业意味着什么
What Sanofi’s multiple sclerosis troubles could mean for the space
艾伯维承诺在特朗普药品定价协议中向美国生产投入1000亿美元。
AbbVie pledges $100B to US production in drug pricing deal with Trump
JPM26:美国生物科技的“斯普特尼克时刻”,辉瑞的减肥药雄心与百时美施贵宝的关键之年
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
艾伯维押注PD-1/VEGF双靶点竞赛;Alnylam与Vertex公布业绩预期
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
2026年生物制药行业面临的五大问题
5 questions facing biopharma in 2026
通过创新打造更可持续的冷链包装
Building more sustainable cold chain packaging through innovation